908 Devices (NASDAQ:MASS) Announces Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Key Points

• 908 Devices reported a wider-than-expected quarterly loss of $0.32 per share versus the $0.14 consensus estimate, though revenue of $16.07 million exceeded expectations and increased 23% year over year.
• Profitability improved as the adjusted EBITDA loss narrowed to $1.9 million and adjusted gross margin reached 57%; management raised the low end of 2026 revenue guidance to $68 million-$70 million.
• The NIRLab acquisition is showing early momentum, but the unresolved AVCAD military program was excluded from guidance. The company ended the quarter with $101.5 million in cash and no debt, while analysts’ average rating remains “Hold” with an $11 price target.

908 Devices (NASDAQ:MASS - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.18), FiscalAI reports. The company had revenue of $16.07 million for the quarter, compared to analysts' expectations of $15.37 million. 908 Devices had a negative net margin of 62.40% and a negative return on equity of 14.03%.

Here are the key takeaways from 908 Devices' conference call:

• Second-quarter revenue rose 23% year over year to $16.1 million, while 198 devices were shipped and the installed base reached 4,101. U.S. state and local customers contributed more than half of quarterly revenue, supported by demand for modernized detection equipment.
• Profitability improved meaningfully, with adjusted EBITDA loss narrowing to $1.9 million from $3.9 million a year earlier and adjusted gross margin expanding to 57%. Management raised the low end of full-year 2026 revenue guidance to $68 million-$70 million, or 21%-25% growth.
• The NIRLab acquisition is gaining early traction, with more than 35 devices sold in roughly two months, each including a multiyear software subscription. Management sees cross-selling potential with MX908 and other products and aspires to increase recurring revenue from its current 31% of total revenue toward 40% over time.
• The AVCAD military program remains unresolved after its current contract ended, with the government evaluating both a continued development path and commercially available products. The company excluded AVCAD from 2026 guidance, although any contribution would be upside and management continues to view it as a potential $10 million-plus long-term opportunity.
• The company ended the quarter with $101.5 million in cash and no debt, but consumed $10.2 million during the quarter, including $13.5 million for the NIRLab acquisition. Management continues to target a mid-single-digit-million adjusted EBITDA loss for 2026 rather than breakeven.

908 Devices Stock Up 3.4%

Shares of NASDAQ:MASS opened at $9.10 on Tuesday. 908 Devices has a 52-week low of $5.03 and a 52-week high of $9.34. The stock has a market cap of $343.96 million, a P/E ratio of -8.99 and a beta of 0.66. The business has a fifty day moving average of $8.21 and a two-hundred day moving average of $7.31.

Insiders Place Their Bets

In related news, CFO Joseph H. Iv Griffith sold 6,940 shares of 908 Devices stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $9.03, for a total value of $62,668.20. Following the completion of the sale, the chief financial officer owned 132,956 shares in the company, valued at approximately $1,200,592.68. This trade represents a 4.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher D. Brown sold 30,000 shares of the firm's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.00, for a total value of $270,000.00. Following the completion of the sale, the director owned 895,559 shares in the company, valued at approximately $8,060,031. This represents a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 89,140 shares of company stock valued at $787,308. Company insiders own 28.20% of the company's stock.

Institutional Investors Weigh In On 908 Devices

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its position in 908 Devices by 5.5% during the second quarter. Rhumbline Advisers now owns 36,416 shares of the company's stock worth $260,000 after acquiring an additional 1,894 shares during the last quarter. Graham Capital Management L.P. grew its position in 908 Devices by 12.9% during the fourth quarter. Graham Capital Management L.P. now owns 20,787 shares of the company's stock valued at $109,000 after acquiring an additional 2,374 shares during the period. Cresset Asset Management LLC grew its stake in 908 Devices by 37.1% during the third quarter. Cresset Asset Management LLC now owns 16,100 shares of the company's stock worth $141,000 after buying an additional 4,355 shares during the period. Barclays PLC lifted its stake in shares of 908 Devices by 15.4% during the fourth quarter. Barclays PLC now owns 44,528 shares of the company's stock worth $234,000 after purchasing an additional 5,943 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in 908 Devices in the second quarter valued at approximately $48,000. Institutional investors and hedge funds own 88.06% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on MASS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 908 Devices in a research note on Friday. Wall Street Zen lowered 908 Devices from a "buy" rating to a "hold" rating in a research note on Saturday, July 18th. Finally, Roth Capital started coverage on 908 Devices in a research report on Wednesday, July 29th. They set a "buy" rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $11.00.

About 908 Devices

908 Devices Inc NASDAQ: MASS is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source